Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis

The natriuretic peptides, atrial (ANP) and brain natriuretic peptide (BNP) are known to suppress cardiac hypertrophy and fibrosis. Both ANP and BNP exert their bioactivities through the Npr1 receptor, and Npr1 knockout mice (Npr1 -/-) exhibit marked cardiac hypertrophy and fibrosis. In this study, we investigated which genes within the hypertrophic and fibrotic pathways are influenced by the lack of Npr1 signalling. cDNA microarray and quantitative real-time PCR (RT-PCR) analyses were performed on cardiac ventricles from Nprl -/- mice. Gene expression at early and late stages during development of hypertrophy was investigated in male and female Nprl -/- mice at 8 weeks and 6 months of age. Heart weight to bodyweight ratios (HW:BW) were maximally increased in 8-week males (P < 0(.)01), whilst HW:BW in females continued to increase progressively up to 6 months (P < 0(.)01). This was despite blood pressure being similarly elevated at both the ages in male and female knockout when compared with wild-type (WT) mice (P < 0(.)001). Microarray analysis identified altered gene expression at the earliest steps in the hypertrophy-signalling cascade in Nprl -/- mice, particularly calcium-calmodulin signalling and ion channels, with subsequent changes in the expression of intracellular messengers including protein kinases and transcription factors. Real-time PCR analysis confirmed significant differences in gene expression of ANP, BNP, calmodulin 1, histone deacetylase 7a (HDAC7a), protein kinase C (PKC)L, (GATA) 4, Collagen 1, phospholamban and transforming growth factor-beta 1 in Nprl -/- mice when compared with WT (P < 0(.)05). The present study implicates the calmodulin-CaMK-Hdac-Mef2 and PKC-MAPK-GATA4 pathways in Nprl mediation of cardiac hypertrophy.